Skip to content
lifestyle.fictiontalk.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HANCHORBIO INC.
Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance
October 30, 2026
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
October 22, 2026
HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy
October 5, 2026
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
September 9, 2026
HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
August 12, 2026
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
July 8, 2026
HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
May 26, 2026